A 45-year-old previously healthy man is admitted to hospital with community-acquired pneumonia. His CURB-65 score is 1. He has no known drug allergies. Chest X-ray shows right lower lobe consolidation. According to BTS guidelines, what is the most appropriate first-line antibiotic regimen for this patient?
Q82
A 72-year-old woman presents to the Emergency Department with a 4-day history of productive cough with green sputum, fever, and right-sided pleuritic chest pain. She lives independently and has no significant past medical history. Observations: temperature 38.7°C, heart rate 98 bpm, respiratory rate 24 breaths/min, blood pressure 125/78 mmHg, oxygen saturation 93% on room air. Examination reveals dullness to percussion and bronchial breathing at the right lung base. Blood tests show: urea 8.2 mmol/L, white cell count 16.5 × 10⁹/L. What is her CURB-65 score?
Q83
A 55-year-old man with severe COPD on triple therapy (ICS/LABA/LAMA) presents with his fourth exacerbation requiring antibiotics and steroids in the past 12 months. He stopped smoking 2 years ago. Blood tests show: eosinophil count 0.05 × 10⁹/L (50 cells/μL). His FEV1 is 38% predicted. Despite optimal inhaler therapy and completion of pulmonary rehabilitation, he remains breathless on minimal exertion. According to NICE guidance, which additional treatment option should be considered?
Q84
A 70-year-old woman with known COPD (FEV1 45% predicted) presents to the Emergency Department with a 3-day history of increased breathlessness, increased sputum volume that is now green in colour, and wheeze. She is on home oxygen therapy 2L/min for 16 hours daily. Observations: respiratory rate 26 breaths/min, oxygen saturation 86% on room air, heart rate 105 bpm, temperature 37.8°C. Arterial blood gas on 28% Venturi mask shows: pH 7.34, PaO2 8.2 kPa, PaCO2 7.1 kPa, HCO3- 32 mmol/L, BE +6. What is the most appropriate immediate management?
Q85
A 62-year-old man with a 45 pack-year smoking history presents to his GP with progressive breathlessness over 2 years and morning cough productive of white sputum. Spirometry shows FEV1 55% predicted, FVC 78% predicted, FEV1/FVC ratio 0.62. Post-bronchodilator testing shows no significant reversibility. He continues to smoke 15 cigarettes daily. According to NICE guidelines, what is the most appropriate initial pharmacological management alongside smoking cessation advice?
Q86
A 35-year-old woman with a history of asthma controlled on beclometasone 400 micrograms twice daily and salbutamol as required presents to the Emergency Department with acute breathlessness. She has had increasing symptoms over 24 hours despite using her salbutamol inhaler every hour. Peak flow is 40% of her best. She receives nebulised salbutamol 5mg, ipratropium bromide 500 micrograms, and oral prednisolone 40mg. After 1 hour, her peak flow remains at 42% of best with persistent wheeze. What is the most appropriate next step in management?
Q87
A 28-year-old man with known asthma presents to the Emergency Department with severe breathlessness and wheeze. He is unable to complete sentences and appears distressed. Observations: heart rate 125 bpm, respiratory rate 28 breaths/min, oxygen saturation 90% on room air, blood pressure 130/80 mmHg. Peak expiratory flow rate is 35% of his best. Chest examination reveals bilateral widespread wheeze with reduced air entry. What defines this presentation as life-threatening asthma?
Q88
A 45-year-old woman presents to her GP with a 6-month history of episodic wheeze and breathlessness, particularly when walking in cold air and at night. She has no significant past medical history and has never smoked. Spirometry shows FEV1 82% predicted, FVC 88% predicted, FEV1/FVC ratio 0.78. Bronchodilator reversibility testing demonstrates a 15% and 250ml improvement in FEV1 after salbutamol. What is the most appropriate initial long-term treatment?
Respiratory Medicine UK Medical PG Practice Questions and MCQs
Question 81: A 45-year-old previously healthy man is admitted to hospital with community-acquired pneumonia. His CURB-65 score is 1. He has no known drug allergies. Chest X-ray shows right lower lobe consolidation. According to BTS guidelines, what is the most appropriate first-line antibiotic regimen for this patient?
A. Oral amoxicillin 500mg three times daily plus clarithromycin 500mg twice daily
B. Oral doxycycline 200mg loading dose then 100mg once daily
C. Intravenous benzylpenicillin 1.2g four times daily
D. Oral amoxicillin 500mg three times daily (Correct Answer)
E. Intravenous co-amoxiclav 1.2g three times daily plus clarithromycin 500mg twice daily
Explanation: ***Oral amoxicillin 500mg three times daily***
- According to **BTS guidelines**, a **CURB-65 score of 1** indicates low-severity community-acquired pneumonia, for which **amoxicillin monotherapy** is the first-line treatment.
- It provides excellent coverage against **Streptococcus pneumoniae**, the most common causative organism in cases of lower-severity pneumonia.
*Oral amoxicillin 500mg three times daily plus clarithromycin 500mg twice daily*
- This dual therapy is recommended for **moderate-severity pneumonia** (CURB-65 score of 2) to cover for **atypical pathogens**.
- Adding a macrolide is not routinely necessary for low-severity cases unless there is an **atypical infection** suspected or a lack of response to monotherapy.
*Oral doxycycline 200mg loading dose then 100mg once daily*
- Doxycycline is recommended as an **alternative first-line** treatment for patients with a **penicillin allergy**.
- Since this patient has **no known drug allergies**, amoxicillin remains the preferred choice.
*Intravenous benzylpenicillin 1.2g four times daily*
- **Intravenous antibiotics** are generally reserved for patients with a **CURB-65 score \u2265 3** or those unable to tolerate oral intake.
- Benzylpenicillin is effective for **confirmed pneumococcal infections** but is not the standard first-line empiric choice for low-severity CAP.
*Intravenous co-amoxiclav 1.2g three times daily plus clarithromycin 500mg twice daily*
- This intensive intravenous regimen is reserved for **high-severity pneumonia** (CURB-65 score of 3 or more).
- Using broad-spectrum combination therapy for a low-severity case violates **antimicrobial stewardship** principles.
Question 82: A 72-year-old woman presents to the Emergency Department with a 4-day history of productive cough with green sputum, fever, and right-sided pleuritic chest pain. She lives independently and has no significant past medical history. Observations: temperature 38.7°C, heart rate 98 bpm, respiratory rate 24 breaths/min, blood pressure 125/78 mmHg, oxygen saturation 93% on room air. Examination reveals dullness to percussion and bronchial breathing at the right lung base. Blood tests show: urea 8.2 mmol/L, white cell count 16.5 × 10⁹/L. What is her CURB-65 score?
A. 2 (Correct Answer)
B. 5
C. 1
D. 3
E. 4
Explanation: ***2***
- The CURB-65 score is calculated based on **Urea >7 mmol/L** (this patient has 8.2 mmol/L) and **Age ≥65** (this patient is 72), giving a total of **2 points**.
- Other criteria like **Confusion**, **Respiratory rate ≥30**, and **low Blood pressure** (systolic <90 or diastolic ≤60) are not present in this clinical scenario.
*5*
- This score would require all five criteria to be positive: **C**onfusion, **U**rea >7, **R**espiratory rate ≥30, **B**lood pressure low, and age **65** or older.
- Since the patient lacks three of these clinical markers, a score of 5 is incorrect and would indicate **extremely high mortality risk**.
*1*
- This score would incorrectly ignore either the patient's **advanced age** (72 years) or her **elevated urea levels** (8.2 mmol/L).
- A score of 1 represents **low risk**, whereas this patient falls into the **moderate risk** category requiring hospital-based care.
*3*
- A score of 3 would be reached if the patient also exhibited **tachypnea (RR ≥30)**, hypotension, or **new-onset confusion**.
- While a score of 3 indicates **severe pneumonia** requiring urgent admission, this patient’s observations do not meet the additional thresholds.
*4*
- For a score of 4, the patient would need to have four out of five factors, such as **systolic BP <90 mmHg** and **AMTS ≤8**.
- This score marks **high severity** and usually mandates consideration for **Intensive Care Unit (ICU)** assessment, which is not indicated here.
Question 83: A 55-year-old man with severe COPD on triple therapy (ICS/LABA/LAMA) presents with his fourth exacerbation requiring antibiotics and steroids in the past 12 months. He stopped smoking 2 years ago. Blood tests show: eosinophil count 0.05 × 10⁹/L (50 cells/μL). His FEV1 is 38% predicted. Despite optimal inhaler therapy and completion of pulmonary rehabilitation, he remains breathless on minimal exertion. According to NICE guidance, which additional treatment option should be considered?
A. Roflumilast (phosphodiesterase-4 inhibitor)
B. Oral prophylactic azithromycin (Correct Answer)
C. Increase inhaled corticosteroid dose
D. Add montelukast
E. Home nebuliser therapy with salbutamol
Explanation: ***Oral prophylactic azithromycin***
- According to **NICE guidelines**, prophylactic **azithromycin** (usually 250mg 3x weekly) is indicated for patients who have optimized triple therapy, are non-smokers, and still experience **frequent exacerbations** (≥3 per year).
- Before initiation, it is essential to perform a **sputum culture** to exclude atypical mycobacteria, check a **baseline ECG** for QT prolongation, and monitor **liver function tests** and **hearing**.
*Roflumilast (phosphodiesterase-4 inhibitor)*
- **Roflumilast** is an option for severe COPD with **chronic bronchitis** and frequent exacerbations, but NICE typically recommends a trial of **azithromycin** as an earlier step in this context.
- It is often limited by a high side-effect profile, particularly **gastrointestinal upset** and weight loss, making it less favorable than macrolide prophylaxis initially.
*Increase inhaled corticosteroid dose*
- Increasing the **ICS dose** beyond standard levels does not provide additional benefit in COPD and significantly increases the risk of **pneumonia**.
- This patient’s **blood eosinophil count** is very low (50 cells/μL), suggesting that they are unlikely to derive further benefit from increased steroid therapy.
*Add montelukast*
- **Montelukast** is a leukotriene receptor antagonist used in the management of **asthma**, but it has no proven role or evidence base for preventing **COPD exacerbations**.
- NICE guidance does not include any recommendation for its use in the routine management of stable **COPD**.
*Home nebuliser therapy with salbutamol*
- **Home nebulisers** are intended for symptom control in patients with persistent, distressing breathlessness despite optimal inhaler technique; they do not specifically target **exacerbation frequency**.
- They should only be provided after a formal assessment by a **specialist respiratory service** to ensure that hand-held devices have been truly exhausted.
Question 84: A 70-year-old woman with known COPD (FEV1 45% predicted) presents to the Emergency Department with a 3-day history of increased breathlessness, increased sputum volume that is now green in colour, and wheeze. She is on home oxygen therapy 2L/min for 16 hours daily. Observations: respiratory rate 26 breaths/min, oxygen saturation 86% on room air, heart rate 105 bpm, temperature 37.8°C. Arterial blood gas on 28% Venturi mask shows: pH 7.34, PaO2 8.2 kPa, PaCO2 7.1 kPa, HCO3- 32 mmol/L, BE +6. What is the most appropriate immediate management?
A. Continue controlled oxygen targeting saturation 88-92%, start antibiotics and steroids, repeat blood gas in 30-60 minutes (Correct Answer)
B. Start high-flow oxygen at 15L/min and prepare for intubation
C. Increase oxygen to achieve target saturation 94-98% and start non-invasive ventilation
D. Reduce oxygen to 24% Venturi mask and give nebulised bronchodilators with air as driving gas
E. Continue 28% oxygen, commence intravenous doxapram infusion
Explanation: ***Continue controlled oxygen targeting saturation 88-92%, start antibiotics and steroids, repeat blood gas in 30-60 minutes***- This approach directly addresses the **acute exacerbation of COPD** with evidence of infection (green sputum) and **type 2 respiratory failure** (hypercapnia with compensated acidosis).- **Controlled oxygen** (88-92% SpO2) prevents exacerbating hypercapnia, while **antibiotics** and **steroids** treat the underlying cause and inflammation, and **repeat ABG** monitors progress.*Start high-flow oxygen at 15L/min and prepare for intubation*- **High-flow oxygen** at 15L/min would likely lead to severe **CO2 retention** in a patient with chronic hypercapnia due to COPD, potentially worsening respiratory acidosis.- While severely ill, the patient's **pH of 7.34** indicates partial compensation, meaning immediate **intubation** is not the first-line intervention and other less invasive methods should be attempted.*Increase oxygen to achieve target saturation 94-98% and start non-invasive ventilation*- A target **oxygen saturation of 94-98%** is too high for this patient with COPD and hypercapnia, as it risks depressing the hypoxic drive and worsening **hypercapnic respiratory failure**.- **Non-invasive ventilation (NIV)** is considered for AECOPD with persistent acidosis (pH <7.35) after optimal medical therapy; it is not typically initiated immediately without a trial of controlled oxygen, steroids, and antibiotics.*Reduce oxygen to 24% Venturi mask and give nebulised bronchodilators with air as driving gas*- Reducing oxygen to 24% Venturi from the current 28% might be insufficient to achieve the target **oxygen saturation 88-92%**, given her current SpO2 of 86% on room air.- While nebulised **bronchodilators** are crucial, delivering them with **air as the driving gas** might reduce oxygenation if the patient is significantly hypoxic and requires supplemental oxygen.*Continue 28% oxygen, commence intravenous doxapram infusion*- **Doxapram** is an outdated respiratory stimulant that has largely been replaced by more effective and safer interventions like **non-invasive ventilation** for managing hypercapnic respiratory failure.- This option lacks the essential components of **antibiotics** and **systemic steroids**, which are critical for treating the underlying infection and inflammation in AECOPD.
Question 85: A 62-year-old man with a 45 pack-year smoking history presents to his GP with progressive breathlessness over 2 years and morning cough productive of white sputum. Spirometry shows FEV1 55% predicted, FVC 78% predicted, FEV1/FVC ratio 0.62. Post-bronchodilator testing shows no significant reversibility. He continues to smoke 15 cigarettes daily. According to NICE guidelines, what is the most appropriate initial pharmacological management alongside smoking cessation advice?
A. Short-acting beta-2 agonist or short-acting muscarinic antagonist as required (Correct Answer)
B. Long-acting beta-2 agonist and long-acting muscarinic antagonist combination
C. Inhaled corticosteroid and long-acting beta-2 agonist combination
D. Oral theophylline
E. Long-acting muscarinic antagonist once daily
Explanation: ***Short-acting beta-2 agonist (SABA) or short-acting muscarinic antagonist (SAMA) as required***
- According to **NICE guidelines (NG115)**, the first-line pharmacological treatment for all patients with newly diagnosed **COPD** is a **short-acting bronchodilator** for symptom relief.
- This patient presents with a new diagnosis confirmed by an **FEV1/FVC ratio < 0.7**, and initial management focuses on PRN (as required) use before escalating to long-acting therapies.
*Long-acting beta-2 agonist (LABA) and long-acting muscarinic antagonist (LAMA) combination*
- **LAMA + LABA** combination is indicated as the next step only if the patient remains symptomatic despite using a **SABA or SAMA**.
- While effective for **GOLD grade 2** or higher, it is not the initial step alongside smoking cessation in a treatment-naive patient.
*Inhaled corticosteroid (ICS) and long-acting beta-2 agonist (LABA) combination*
- **ICS/LABA** therapy is reserved for patients with features of **asthma-COPD overlap** or those who continue to have exacerbations.
- This patient lacks **asthmatic features** (e.g., high eosinophil count, diurnal variation) and has no history of frequent exacerbations.
*Oral theophylline*
- **Theophylline** is typically considered only after trials of **short-acting** and **long-acting bronchodilators** have failed or are not tolerated.
- It requires **plasma level monitoring** due to its narrow therapeutic index and numerous drug interactions.
*Long-acting muscarinic antagonist (LAMA) once daily*
- Monotherapy with a **LAMA** is a maintenance option if short-acting agents are insufficient, but it is not the recommended starting point.
- NICE pathways suggest moving to **long-acting bronchodilators** based on the presence or absence of **asthmatic features** after initial SABA/SAMA trial.
Question 86: A 35-year-old woman with a history of asthma controlled on beclometasone 400 micrograms twice daily and salbutamol as required presents to the Emergency Department with acute breathlessness. She has had increasing symptoms over 24 hours despite using her salbutamol inhaler every hour. Peak flow is 40% of her best. She receives nebulised salbutamol 5mg, ipratropium bromide 500 micrograms, and oral prednisolone 40mg. After 1 hour, her peak flow remains at 42% of best with persistent wheeze. What is the most appropriate next step in management?
A. Repeat nebulised bronchodilators and reassess in another hour
B. Discharge with increased inhaled corticosteroid dose and oral prednisolone course
C. Commence intravenous magnesium sulphate 2g over 20 minutes (Correct Answer)
D. Start intravenous aminophylline infusion
E. Arrange non-invasive ventilation
Explanation: ***Commence intravenous magnesium sulphate 2g over 20 minutes*** - The patient presents with **acute severe asthma** as evidenced by a **peak flow of 40-42%** of best and poor response to initial therapy including nebulised bronchodilators and oral corticosteroids. - **Intravenous magnesium sulphate** is indicated as a second-line bronchodilator for patients with acute severe asthma who do not respond adequately to initial inhaled bronchodilators and systemic corticosteroids. *Repeat nebulised bronchodilators and reassess in another hour* - The patient has already received initial aggressive nebulised therapy and shown minimal improvement (PEFR 40% to 42%), indicating **refractory bronchospasm**. - Repeating the same intervention without escalation delays more definitive treatment and risks **clinical deterioration** in a severe asthmatic. *Discharge with increased inhaled corticosteroid dose and oral prednisolone course* - Discharge is unsafe and inappropriate given the patient's **persistent severe symptoms** and significantly reduced lung function (PEFR 42% of best). - Patients with acute asthma should only be discharged once their **peak flow is >75% of best or predicted** and they are symptomatically stable. *Start intravenous aminophylline infusion* - **Intravenous aminophylline** is generally considered a **third-line treatment** for acute severe asthma, typically reserved for cases unresponsive to magnesium sulphate. - It has a **narrow therapeutic index** and a higher risk of adverse effects compared to magnesium sulphate, which is preferred as the next step. *Arrange non-invasive ventilation* - **Non-invasive ventilation (NIV)** is generally **not recommended** in acute severe asthma due to the risk of air trapping, barotrauma, and potential for delaying intubation. - If a patient develops **respiratory failure** with hypercapnia or exhaustion, **invasive mechanical ventilation** is the appropriate management.
Question 87: A 28-year-old man with known asthma presents to the Emergency Department with severe breathlessness and wheeze. He is unable to complete sentences and appears distressed. Observations: heart rate 125 bpm, respiratory rate 28 breaths/min, oxygen saturation 90% on room air, blood pressure 130/80 mmHg. Peak expiratory flow rate is 35% of his best. Chest examination reveals bilateral widespread wheeze with reduced air entry. What defines this presentation as life-threatening asthma?
A. Respiratory rate of 28 breaths per minute
B. Peak flow 35% of best predicted value
C. Oxygen saturation 90% on room air (Correct Answer)
D. Heart rate of 125 beats per minute
E. Inability to complete sentences in one breath
Explanation: ***Oxygen saturation 90% on room air***- An **SpO2 <92%** is a key clinical indicator of **life-threatening asthma** according to BTS/SIGN clinical guidelines.- This level of hypoxia signifies significant **ventilation-perfusion mismatch** or respiratory fatigue, necessitating immediate senior intervention.*Respiratory rate of 28 breaths per minute*- A respiratory rate **≥25 breaths/min** is a criteria used to define **acute severe asthma**, not life-threatening features.- In life-threatening asthma, the respiratory rate may actually fall as the patient becomes **exhausted** or shows poor respiratory effort.*Peak flow 35% of best predicted value*- A peak expiratory flow (PEF) of **33-50%** of the patient's best or predicted value defines **acute severe asthma**.- To be classified as **life-threatening**, the PEF must be **<33%** of the best or predicted value.*Heart rate of 125 beats per minute*- A heart rate **>110 beats/min** is a feature of **acute severe asthma** due to sympathetic drive and stress.- Life-threatening asthma is instead associated with **arrhythmias** or **hypotension** as the physiological compensatory mechanisms fail.*Inability to complete sentences in one breath*- The inability to complete sentences in one breath is a classic hallmark of **acute severe asthma**.- While serious, it does not move the classification to **life-threatening** unless accompanied by signs like a **silent chest**, cyanosis, or altered consciousness.
Question 88: A 45-year-old woman presents to her GP with a 6-month history of episodic wheeze and breathlessness, particularly when walking in cold air and at night. She has no significant past medical history and has never smoked. Spirometry shows FEV1 82% predicted, FVC 88% predicted, FEV1/FVC ratio 0.78. Bronchodilator reversibility testing demonstrates a 15% and 250ml improvement in FEV1 after salbutamol. What is the most appropriate initial long-term treatment?
A. Regular low-dose inhaled corticosteroid (Correct Answer)
B. Combined inhaled corticosteroid and long-acting beta-2 agonist
C. Short-acting beta-2 agonist as required only
D. Long-acting beta-2 agonist twice daily
E. Leukotriene receptor antagonist
Explanation: ***Regular low-dose inhaled corticosteroid***- This patient has confirmed **asthma** based on clinical symptoms and a significant **bronchodilator reversibility** test (improvement >12% and >200ml).- **Inhaled corticosteroids (ICS)** are the first-line long-term preventer therapy to address underlying **airway inflammation**, reduce symptoms, and prevent exacerbations.*Combined inhaled corticosteroid and long-acting beta-2 agonist*- **Combination therapy (ICS/LABA)** is typically reserved for patients whose asthma is not adequately controlled on **low-dose ICS** monotherapy alone.- Starting with a combination inhaler is considered **step 3** of management, whereas this patient requires initial maintenance therapy.*Short-acting beta-2 agonist as required only*- **SABA monotherapy** is and should only be used for very infrequent symptoms; however, guidelines increasingly favor **low-dose ICS** for all patients to mitigate the risk of severe attacks.- This patient reports **nocturnal symptoms** and exercise-induced wheeze, indicating a need for regular **preventer treatment** rather than just rescue therapy.*Long-acting beta-2 agonist twice daily*- **LABA monotherapy** is strictly contraindicated in the treatment of asthma due to an increased risk of severe and potentially fatal **asthma exacerbations**.- A **LABA** must always be prescribed in conjunction with an **inhaled corticosteroid** to ensure the inflammatory component of the disease is treated.*Leukotriene receptor antagonist*- **Leukotriene receptor antagonists (LTRAs)**, such as Montelukast, are typically used as **add-on therapy** to ICS rather than first-line monotherapy.- While effective for exercise-induced symptoms, they are generally less potent than **inhaled corticosteroids** at improving lung function and overall control.
